Un primer estudio en humano de KK2223 en participantes con linfoma no Hodgkin de células T recurrentes o refractarias
Un estudio de fase 1, multicéntrico, abierto, no aleatorizado, escala de dosis y relleno de KK2223 en participantes con linfoma no Hodgkin de células T recurrentes o refractarias
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Kyowa Kirin, Inc.
- Número de teléfono: +1-609-919-1100
- Correo electrónico: KKD.Clinical.82@kyowakirin.com
Ubicaciones de estudio
-
-
-
Madrid, España, 28027
- Aún no reclutando
- Clinica Universidad de Navarra - Hematología y Hemoterapia
-
Contacto:
- Miguel Canales Albendea
- Número de teléfono: 34917277116
- Correo electrónico: macanales@unav.es
-
Investigador principal:
- Migue Canales Albendea
-
-
Barcelona
-
Badalona, Barcelona, España, 8036
- Aún no reclutando
- Hospital Clinic De Barcelona - Hematología
-
Investigador principal:
- Pablo Mozas
-
Contacto:
- Pablo Mozas
- Número de teléfono: 34 93 227 22 71
- Correo electrónico: mozas@clinic.cat
-
L'Hospitalet de Llobregat, Barcelona, España, 8907
- Aún no reclutando
- Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
-
Investigador principal:
- Eva Domingo Domenech
-
Contacto:
- Eva Domingo Domenech
- Número de teléfono: 34932607822
- Correo electrónico: edomingo@iconcologia.net
-
-
Navarre
-
Pamplona, Navarre, España, 31008
- Aún no reclutando
- Clinica Universidad de Navarra - Hematología
-
Contacto:
- Miguel Canales Albendea
- Número de teléfono: 34917277116
- Correo electrónico: macanales@unav.es
-
Investigador principal:
- Miguel Canales Albendea
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Aún no reclutando
- City of Hope
-
Investigador principal:
- Christina Poh
-
Contacto:
- Christina Poh
- Número de teléfono: 916-734-7131
- Correo electrónico: cpoh@coh.org
-
Orange, California, Estados Unidos, 92868
- Aún no reclutando
- University of California, Irvine Medical Center - Hematology/Oncology
-
Contacto:
- Lauren Pinter Brown
- Número de teléfono: 7144568200
- Correo electrónico: lpinterb@uci.edu
-
Investigador principal:
- Lauren Pinter Brown
-
Stanford, California, Estados Unidos, 94305
- Reclutamiento
- Stanford University School of Medicine
-
Investigador principal:
- Youn Kim
-
Contacto:
- Youn Kim
- Número de teléfono: 650-723-7893
- Correo electrónico: younkim@stanford.edu
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Aún no reclutando
- Moffit Cancer Center
-
Contacto:
- Yumeng Zhang
- Número de teléfono: 844-304-8636
- Correo electrónico: yumeng.zhang@moffitt.org
-
Investigador principal:
- Yumeng Zhang
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Aún no reclutando
- Emory University Medical Center
-
Investigador principal:
- Pamela Allen
-
Contacto:
- Pamela Allen
- Número de teléfono: 404-778-2407
- Correo electrónico: pallen5@emory.edu
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Aún no reclutando
- University of Iowa Health
-
Investigador principal:
- Eric Mou
-
Contacto:
- Eric Mou
- Número de teléfono: 800-777-8442
- Correo electrónico: eric-mou@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Aún no reclutando
- Beth Israel Deaconess Medical Center - Research
-
Contacto:
- Salvia Jain
- Número de teléfono: 617-726-2000
- Correo electrónico: salvia.jain@mgh.harvard.edu
-
Investigador principal:
- Salvia Jain
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Washington University School of Medicine - Oncology Hospital - Public
-
Investigador principal:
- Neha Mehta Shah
-
Contacto:
- Neha Mehta Shah
- Número de teléfono: 314.273-8566
- Correo electrónico: mehta-n@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601-2105
- Aún no reclutando
- Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
-
Investigador principal:
- Tatyana Feldman
-
Contacto:
- Tatyana Feldman
- Número de teléfono: 551-996-5900
- Correo electrónico: tatyana.feldman@hmhn.org
-
-
New York
-
New York, New York, Estados Unidos, 10021-6007
- Reclutamiento
- Memorial Sloan Kettering Cancer Center
-
Investigador principal:
- Jasmine Zain
-
Contacto:
- Jasmine Zain
- Número de teléfono: 212-639-3045
- Correo electrónico: zainj1@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Aún no reclutando
- University Hospitals Cleveland Medical Center
-
Contacto:
- Kevin Cooper
- Número de teléfono: 216-844-8200
- Correo electrónico: kevin.cooper@uhhospitals.org
-
Investigador principal:
- Kevin Cooper
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Aún no reclutando
- Oregon Health & Science University
-
Contacto:
- Craig Okada
- Número de teléfono: 503-494-8397
- Correo electrónico: okadac@ohsu.edu
-
Investigador principal:
- Craig Okada
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Aún no reclutando
- University of Pennsylvania - Abramson Cancer Center
-
Investigador principal:
- Stefan Barta
-
Contacto:
- Stefan Barta
- Número de teléfono: 215-728-2674
- Correo electrónico: Stefan.Barta@pennmedicine.upenn.edu
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- The University of Texas - MD Anderson Cancer Center
-
Investigador principal:
- Ranjit Nair
-
Contacto:
- Ranjit Nair
- Número de teléfono: 171-379-2860
- Correo electrónico: rnair@mdanderson.org
-
-
-
-
-
Bergamo, Italia, 24127
- Aún no reclutando
- Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
-
Investigador principal:
- Giuseppe Gritti
-
Contacto:
- Giuseppe Gritti
- Número de teléfono: 39035269492
- Correo electrónico: giuseppe_gritti@yahoo.it
-
Bologna, Italia, 40138
- Aún no reclutando
- Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
-
Contacto:
- Luigi Zinzani Pier
- Número de teléfono: 390516363680
- Correo electrónico: pierluigi.zinzani@unibo.it
-
Investigador principal:
- Luigi Zinzani Pier
-
Torino, Italia, 10126
- Aún no reclutando
- AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
-
Contacto:
- Federica Cavallo
- Número de teléfono: 390116334264
- Correo electrónico: f.cavallo@unito.it
-
Investigador principal:
- Federica Cavallo
-
-
Torino
-
Candiolo, Torino, Italia, 10060
- Aún no reclutando
- Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
-
Investigador principal:
- Umberto Vitolo
-
Contacto:
- Umberto Vitolo
- Número de teléfono: 390116335934
- Correo electrónico: umberto.vitolo@ircc.it
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
- PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
- Availability of tumor tissue (current or archival) is required.
- Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
- ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
- Body weight 40 kg to ≤ 200 kg
- Life expectancy ≥3 months.
- Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
- Restrictions on gamete donation and freezing during and after treatment.
- Ability to provide informed consent and comply with study procedures. -
Exclusion Criteria:
- Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
- Pregnant or breastfeeding females, or those intending pregnancy.
- History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
- Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
- Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
- Use of other investigational drugs within 14 days or 5 half-lives before treatment.
- Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
- Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
- Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
- Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
- Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
- Prolonged QT/QTc interval (e.g., QTcF >480 ms).
- Active second primary malignancies except specified non-exclusionary cases.
- CNS involvement.
- Any condition that may impair compliance or study completion as judged by the Investigator.
- Known hypersensitivity to any excipients in the drug formulation.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Part One (Dose Escalation)
In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design. |
Intravenous infusion |
|
Experimental: Part Two (Backfill)
Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment. |
Intravenous infusion |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Vital signs (mmHg in Systolic/Diastolic blood pressure) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Pulse rate (beats/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Respiratory Rate (breath/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Temperature (°Celcius) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
ECG parameters (PR interval, QRS interval, QT interval, QTc interval) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD) |
Through study completion, an average of 1.5 years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mean Blood Drug Concentration
Periodo de tiempo: Through study completion, an average of 1.5 years
|
The mean drug concentration in the blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the immunogenicity of KK2223.
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Incidence of Anti drug antibodies (ADA) in blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
% in Overall Response Rate (ORR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
% in Compartment Response (if applicable) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Duration of Response (DOR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Response (TTR) |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
Periodo de tiempo: Through study completion, an average of 1.5 years
|
The maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
Periodo de tiempo: Through study completion, an average of 1.5 years
|
A measure of the overall drug exposure over time |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Periodo de tiempo: Through study completion, an average of 1.5 years
|
The time taken to reach the maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
Periodo de tiempo: Through study completion, an average of 1.5 years
|
The time required for the drug concentration to decrease by 50% |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Clearance (CL)
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Rate of drug elimination from the body |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
Periodo de tiempo: Through study completion, an average of 1.5 years
|
Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues |
Through study completion, an average of 1.5 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Linfoma de células T
- Enfermedades hemic y linfáticas
- Neoplasias
- Linfoma
- Linfoma De Células T Periférico
- Linfoma, De Células T, Cutáneo
- Enfermedades del sistema inmunológico
- Micosis Fungoide
- Síndrome de Sézary
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2223-001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .